 |
Partners' Directory |
| Home Search Join the Partnership Login | |
| Contact | General | Specializations in Countries | Contribution to the Global Plan | Declaration |
View this partner's profile
Organization Contact Information | |
| Name: | Dong-A Pharmaceuticals Co., Ltd. |
| Street 1: | 252 Yongdu-dong Dongdaemun-ku, Seoul, S. Korea |
| Street 2: | |
| City: | Seoul |
| Province: | |
| Post Code: | |
| Country: | Republic of Korea |
| Phone: | +82-2-920-8396 |
| Email: | rsy@donga.co.kr |
| Web Site: | http://en.donga.co.kr/ |
|
|
||||||||||||||||||||||||||||
General Information | |
| Board Constituency: | Private sector |
| Organization Type - Primary: | Private Sector |
| Organization Type - Secondary: | Company |
| Is your organization legally registered in your country: | Yes |
| Organization Reach: | International |
| Organization Description: | |
| 1) Dong-A Pharmaceuticals is the No. 1 Pharmacuetical company in Korea and have been so since 1967. We have 80 years of experience in this field and have recently started to implement a plan to become a major player in pharmaceuticals globally. 2) We are the world's largest manufacturer of the MDR-TB API Cycloserine and want to provide the patients of TB with the essential healthcare the need. 3) We will continue to provide manufacturing for Cycloserine and seek out new ways to collaborate with the WHO & STOP TB Partnership to provide better healthcare for mankind around the world. |
|
| Total number of staff in your organization: | 100 + |
| Number of full-time staff who are directly involved with TB: | 1 - 5 |
| Number of part-time staff who are directly involved with TB: | 1 - 5 |
| Number of volunteers who are directly involved with TB: | 1 - 5 |
| What is your organization's annual budget (USD) dedicated to TB? | Unable to disclose amount |
| How did you hear about the Stop TB Partnership: | Other partners |
| Why do you wish join the Stop TB Partnership: | Information on developments within the TB world |
| Are you a member of a Stop TB national partnership: | Republic of Korea |
| Are you in contact with your national TB programme: | Yes |
| Please tell us how your organization is contributing to your country's national TB control plan: | |
| We are currently manufacturing Cycloserine API and the finished product. | |
Geographical Reach | |
| Which country is your headquarters located in: | Republic of Korea |
| Which WHO region is the main focus of your work: | Global |
| Which countries do you do operate in: (This includes countries you are conducting activities in) |
Argentina Australia Bolivia Brazil Cambodia Colombia Germany India Japan Jordan Malaysia Mexico Mongolia Myanmar Nigeria Pakistan Paraguay Republic of Korea Russian Federation Singapore South Africa Turkey United Arab Emirates United States of America Venezuela Viet Nam |
Specializations | |
|
Provision of drugs, diagnostics and commodities Research and Development |
Specializations in Countries | |
| Provision of drugs, diagnostics and commodities | Argentina |
| Provision of drugs, diagnostics and commodities | Australia |
| Provision of drugs, diagnostics and commodities | Bolivia |
| Provision of drugs, diagnostics and commodities | Brazil |
| Provision of drugs, diagnostics and commodities | Cambodia |
| Provision of drugs, diagnostics and commodities | Colombia |
| Provision of drugs, diagnostics and commodities | Germany |
| Provision of drugs, diagnostics and commodities | India |
| Provision of drugs, diagnostics and commodities | Japan |
| Provision of drugs, diagnostics and commodities | Jordan |
| Provision of drugs, diagnostics and commodities | Malaysia |
| Provision of drugs, diagnostics and commodities | Mexico |
| Provision of drugs, diagnostics and commodities | Mongolia |
| Provision of drugs, diagnostics and commodities | Myanmar |
| Provision of drugs, diagnostics and commodities | Nigeria |
| Provision of drugs, diagnostics and commodities | Pakistan |
| Provision of drugs, diagnostics and commodities | Paraguay |
| Provision of drugs, diagnostics and commodities | Republic of Korea |
| Provision of drugs, diagnostics and commodities | Russian Federation |
| Provision of drugs, diagnostics and commodities | Singapore |
| Provision of drugs, diagnostics and commodities | South Africa |
| Provision of drugs, diagnostics and commodities | Turkey |
| Provision of drugs, diagnostics and commodities | United Arab Emirates |
| Provision of drugs, diagnostics and commodities | United States of America |
| Provision of drugs, diagnostics and commodities | Venezuela |
| Provision of drugs, diagnostics and commodities | Viet Nam |
Contribution | |
| Please tell us how your organization will contribute to the Global Plan to Stop TB by briefly describing its involvement in any of the areas of work listed below: | |
|
Drug-Resistant TB: We are currently manufacturing the API Cycloserin and the FPP of Cycloserine. We are distributing to Pakistan, Vietnam, and Korea. We are currently trying to register in the 24 high burden MDR-TB countries and want to partner with the STOP TB Partnership to provide our product to the paitents of MDR-TB around the world. |
|
Declaration | |
| Declaration of interests: No conflicts of interest were delacred. | |
| Application date: | June 19, 2012 |
| Last updated: | June 19, 2012 |